Fibromyalgia with elevated rheumatoid factor is associated with poor therapeutic response but not with progression to rheumatoid arthritis. Prospective cohort study

Reumatologia clinica Pub Date : 2024-11-01 DOI:10.1016/j.reumae.2024.10.001

Freddy Liñán Ponce, Juan Leiva Goicochea, David Sevilla Rodríguez, Elmer Hidalgo Bravo, Ginna Obregón Atanacio, Inés Loyola Macalapú, Paola Jáuregui Rojas, Jackeline Yampufe Canani

{"title":"Fibromyalgia with elevated rheumatoid factor is associated with poor therapeutic response but not with progression to rheumatoid arthritis. Prospective cohort study","authors":"Freddy Liñán Ponce, Juan Leiva Goicochea, David Sevilla Rodríguez, Elmer Hidalgo Bravo, Ginna Obregón Atanacio, Inés Loyola Macalapú, Paola Jáuregui Rojas, Jackeline Yampufe Canani","doi":"10.1016/j.reumae.2024.10.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objetive</h3><div>Evaluate response to treatment and progression to rheumatoid arthritis (RA) in patients with fibromyalgia (FM) associated with elevated rheumatoid factor (RF).</div></div><div><h3>Material and methods</h3><div>Prospective cohort study. The sample consisted of 124 patients with FM: 62 with high RF (>20 U/mL) and 62 with negative RF (0−20 U/mL). All patients were evaluated using FM treatment improvement score (FIQR) and progression to RA according to EULAR/ACR 2010 criteria at 6 and 12 months. Pearson's χ<sup>2</sup> test for homogeneity was used to relate variables of improvement to FM treatment and progression to RA.</div></div><div><h3>Results</h3><div>The response to treatment was lower in the high RF group (24 and 20 patients improved at 6 and 12 months, respectively, compared to 45 and 38 patients in the negative RF group), with a significant difference. Progression to rheumatoid arthritis was similar in both groups (5 in the high RF group and 4 in the negative RF group), with a non-significant relationship.</div></div><div><h3>Conclusions</h3><div>FM with elevated RF is associated with a poor therapeutic response but not with progression to RA.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 9","pages":"Pages 459-462"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatologia clinica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173574324001266","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objetive

Evaluate response to treatment and progression to rheumatoid arthritis (RA) in patients with fibromyalgia (FM) associated with elevated rheumatoid factor (RF).

Material and methods

Prospective cohort study. The sample consisted of 124 patients with FM: 62 with high RF (>20 U/mL) and 62 with negative RF (0−20 U/mL). All patients were evaluated using FM treatment improvement score (FIQR) and progression to RA according to EULAR/ACR 2010 criteria at 6 and 12 months. Pearson's χ² test for homogeneity was used to relate variables of improvement to FM treatment and progression to RA.

Results

The response to treatment was lower in the high RF group (24 and 20 patients improved at 6 and 12 months, respectively, compared to 45 and 38 patients in the negative RF group), with a significant difference. Progression to rheumatoid arthritis was similar in both groups (5 in the high RF group and 4 in the negative RF group), with a non-significant relationship.

Conclusions

FM with elevated RF is associated with a poor therapeutic response but not with progression to RA.

查看原文本刊更多论文

类风湿因子升高的纤维肌痛与治疗反应不佳有关，但与类风湿关节炎的进展无关。前瞻性队列研究。

目的：评估伴有类风湿因子（RF）升高的纤维肌痛（FM）患者对治疗的反应和类风湿关节炎（RA）的进展情况：评估伴有类风湿因子（RF）升高的纤维肌痛（FM）患者对治疗的反应以及向类风湿关节炎（RA）发展的情况：前瞻性队列研究。样本包括 124 名纤维肌痛患者：62 名 RF 高（>20 U/mL），62 名 RF 阴性（0-20 U/mL）。根据 EULAR/ACR 2010 标准，使用 FM 治疗改善评分（FIQR）对所有患者进行评估，并在 6 个月和 12 个月后评估其是否进展为 RA。用皮尔逊χ2检验同质性，将FM治疗改善和RA进展变量联系起来：高射频组的治疗反应较低（6个月和12个月时分别有24名和20名患者病情好转，而阴性射频组分别有45名和38名患者病情好转），差异显著。两组患者发展为类风湿性关节炎的情况相似（高RF组5例，阴性RF组4例），但无显著关系：RF升高的调频与治疗反应差有关，但与类风湿关节炎的进展无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Reumatologia clinica

自引率

0.00%

发文量